How to Get Eylea and Lucentis Covered by Blue Cross Blue Shield in Pennsylvania: Appeals, Forms, and State Protections
Answer Box: Getting Eylea/Lucentis Covered in Pennsylvania
If Blue Cross Blue Shield denied your Eylea (aflibercept) or Lucentis (ranibizumab) for wet AMD or diabetic macular edema, you have strong appeal options in Pennsylvania. Submit prior authorization through your BCBS portal with complete OCT/visual acuity documentation. If denied, use Pennsylvania's new Independent External Review program—launched in 2024, it overturns 50% of denials. First step today: Gather your denial letter, medical records, and contact your eye doctor to request a peer-to-peer review with BCBS medical director.
Table of Contents
- Why Pennsylvania State Rules Matter
- BCBS Pennsylvania Prior Authorization Requirements
- Step Therapy Protections and Medical Exceptions
- Appeals Process: Internal to External Review
- Pennsylvania's Independent External Review Program
- Continuity of Care Protections
- Practical Scripts and Documentation
- When to Escalate to State Regulators
- FAQ: Common Questions
- Sources and Further Reading
Why Pennsylvania State Rules Matter
Pennsylvania's insurance landscape differs significantly from other states, especially since launching its own external review program in January 2024. The state has two major Blue Cross Blue Shield plans: Highmark Blue Shield (serving western and central PA) and Independence Blue Cross (covering eastern and southeastern regions including Philadelphia).
Each plan operates under Pennsylvania insurance regulations but maintains separate formularies and prior authorization processes. Understanding these nuances is crucial because what works for a Highmark member in Pittsburgh may not apply to an Independence Blue Cross member in Philadelphia.
Note: Self-funded employer plans (ERISA-governed) may have different appeal rights and aren't subject to Pennsylvania's external review program. Check with your HR department to confirm your plan type.
BCBS Pennsylvania Prior Authorization Requirements
Coverage at a Glance
| Requirement | Highmark Blue Shield | Independence Blue Cross | Documentation Needed |
|---|---|---|---|
| PA Required | Yes (verify current list) | Yes (verify current list) | Submit via Availity portal |
| Submission Method | Availity portal, 14 days advance | Availity portal, 48 hours emergency | Clinical notes, OCT results |
| Formulary Status | Plan-specific | Plan-specific | Check member formulary |
| Step Therapy | May require bevacizumab first | May require bevacizumab first | Document failure/contraindication |
Key Submission Requirements
Both Pennsylvania BCBS plans require prior authorization requests through the Availity portal with these essential elements:
- Complete member information and highest in-network provider details
- ICD-10 diagnosis codes (H35.32 for wet AMD, E11.311 for diabetic macular edema)
- OCT imaging showing retinal fluid or anatomical changes
- Visual acuity measurements demonstrating impairment
- Documentation of medical necessity aligned with FDA labeling
Highmark Blue Shield: Submit at least 14 days prior to treatment, or within 48 hours for emergencies. Contact provider services at 1-800-241-2904 for assistance.
Independence Blue Cross: Similar timelines apply. Use the provider portal at ibx.com or call for urgent submissions.
Tip: Claims submitted without proper prior authorization will be automatically denied, requiring you to restart the entire process.
Step Therapy Protections and Medical Exceptions
Pennsylvania doesn't have specific ophthalmology carve-outs from step therapy requirements, but general reforms provide several exception pathways for anti-VEGF therapies.
Common Step Therapy Sequence
Many BCBS Pennsylvania plans require trying bevacizumab (Avastin) first before approving Eylea or Lucentis, due to cost considerations. However, you can bypass this requirement with proper documentation.
Medical Exception Criteria
| Exception Type | Required Documentation | Timeline |
|---|---|---|
| Treatment Failure | Chart notes showing inadequate response after 30-90 days | 30-90 days trial |
| Contraindication | Provider attestation plus supporting labs/imaging | Immediate |
| Intolerance | Documented side effects (inflammation, allergic reaction) | ≥30 days |
How to Document Exceptions
- Failure Documentation: Include visual acuity measurements, OCT findings showing persistent fluid, and provider notes indicating lack of efficacy
- Contraindication Evidence: Document allergies, active infections, or medical conditions that make bevacizumab inappropriate
- Provider Attestation: Pennsylvania law accepts provider statements as sufficient evidence for medical exceptions
Appeals Process: Internal to External Review
When BCBS denies your Eylea or Lucentis request, you have multiple appeal levels available in Pennsylvania.
Step-by-Step Appeals Process
- Internal Appeal (First Level)
- Timeline: Submit within 30 calendar days of denial
- Method: Online portal, phone, or written request
- Documents: Include denial letter, medical records, provider statement
- Decision: 30 days for standard, 72 hours for urgent
- Internal Appeal (Second Level)
- Timeline: 30 days from first-level denial
- Review: Different medical reviewer than first level
- Decision: 30 days standard, 72 hours urgent
- External Review
- Eligibility: After exhausting internal appeals
- Timeline: 4 months to request after final denial
- Cost: Free to consumer
- Success Rate: 50% overturn rate in Pennsylvania
Required Documentation for Appeals
- Original denial letter with specific reason codes
- Complete medical records supporting medical necessity
- Provider letter explaining why Eylea/Lucentis is appropriate
- Visual acuity measurements and OCT imaging
- Documentation of failed prior therapies (if applicable)
Pennsylvania's Independent External Review Program
Pennsylvania's game-changing external review program launched in January 2024 has already helped hundreds of patients get coverage for initially denied treatments.
Key Program Statistics
- 517 appeals processed in first year (2024)
- 50.1% success rate (259 overturned denials)
- Free to consumers with binding decisions on insurers
How the Process Works
- Submit Request: Use the online portal at pa.gov/reviewmyclaim
- Eligibility Check: Pennsylvania Insurance Department verifies with your insurer (5 business days)
- Independent Review: Third-party medical experts review your case (45 days standard, 72 hours expedited)
- Final Decision: Binding on insurer; coverage must be provided if overturned
Timeline Breakdown
| Step | Standard Timeline | Expedited Timeline |
|---|---|---|
| PID sends to insurer | 1 business day | 24 hours |
| Eligibility determination | 5 business days | 24 hours |
| IRO assignment | 1 business day | Immediate |
| Submit additional info | 15 days from assignment | N/A |
| Final decision | 45 calendar days | 72 hours |
Important: You can submit additional medical evidence directly to the independent review organization within 15 days of assignment to strengthen your case.
Continuity of Care Protections
Pennsylvania's new Fair Contracting for Health Care Practitioners Act (effective January 2025) provides important protections if your eye doctor changes practices or insurance networks.
Key Protections
- Noncompete restrictions prevent employers from limiting where doctors can practice
- Patient notification requirements ensure you're informed if your doctor leaves a practice
- 90-day notification period gives you time to arrange record transfers and continue care
Practical Impact for Ongoing Treatment
If you're receiving regular Eylea or Lucentis injections and your retina specialist changes practices:
- Automatic notification of the change and your options
- Medical record transfer process to maintain continuity
- No treatment gaps due to provider transitions
- Insurance coverage continuity for ongoing therapy
This protection is especially valuable for anti-VEGF therapy, which requires consistent monitoring and regular injections to prevent vision loss.
Practical Scripts and Documentation
Phone Script for BCBS Member Services
"I'm calling about a prior authorization denial for Eylea [or Lucentis] for wet macular degeneration. I'd like to request a peer-to-peer review between my retina specialist and your medical director. Can you schedule this and provide the direct number for my doctor to call?"
Medical Necessity Letter Checklist
Your eye doctor's appeal letter should include:
- Specific diagnosis with ICD-10 codes
- Visual acuity measurements showing impairment
- OCT imaging results demonstrating retinal fluid
- Prior treatment history and outcomes
- Clinical rationale for Eylea/Lucentis over alternatives
- Treatment goals and monitoring plan
- Relevant guidelines (American Academy of Ophthalmology, FDA labeling)
Documentation Phrases That Help
- "Medically necessary to prevent irreversible vision loss"
- "FDA-approved indication for [specific condition]"
- "Failed adequate trial of [alternative therapy] due to [specific reason]"
- "Contraindicated due to [medical condition/allergy]"
- "Consistent with standard of care guidelines"
When to Escalate to State Regulators
If you've exhausted appeals and external review without success, Pennsylvania offers additional consumer protections.
Pennsylvania Insurance Department
- Consumer Services: 1-877-881-6388
- Online complaints: Available through pa.gov
- Assistance with: Coverage disputes, claim denials, unfair practices
When to File a Complaint
- Insurer fails to follow Pennsylvania appeal timelines
- Denial appears to violate state insurance laws
- Procedural violations during review process
- Discrimination based on medical condition
FAQ: Common Questions
Q: How long does BCBS prior authorization take in Pennsylvania? A: Both Highmark and Independence Blue Cross don't specify exact turnaround times for specialty drug approvals. Follow up after 2 business days if you haven't received a response.
Q: What if Eylea or Lucentis isn't on my formulary? A: You can request a formulary exception through the same prior authorization process. Include documentation showing why formulary alternatives aren't appropriate.
Q: Can I get an expedited appeal for vision-threatening conditions? A: Yes. Both wet AMD and diabetic macular edema can qualify for urgent appeals (72-hour timeline) if there's risk of irreversible vision loss.
Q: Does step therapy apply if I tried bevacizumab outside Pennsylvania? A: Previous trials from other states typically count toward step therapy requirements. Provide documentation of the trial and outcome.
Q: What's the difference between Highmark and Independence Blue Cross? A: They're separate companies serving different regions of Pennsylvania, with different formularies and policies. Check which plan you have on your insurance card.
Q: How much does external review cost? A: Pennsylvania's Independent External Review program is completely free to consumers.
About Counterforce Health: Counterforce Health helps patients and clinicians navigate complex prior authorization and appeals processes by creating evidence-backed, targeted appeals that address specific payer requirements. The platform specializes in turning insurance denials into successful approvals through comprehensive documentation and strategic appeal strategies.
When dealing with BCBS denials for specialty medications like Eylea and Lucentis, having the right documentation and understanding payer-specific requirements can make the difference between approval and continued denials. Counterforce Health's approach of aligning appeals with each plan's specific criteria has helped many patients access necessary treatments.
Sources and Further Reading
- Pennsylvania Insurance Department External Review Program
- Highmark Provider Manual - Authorizations
- Independence Blue Cross Prior Authorization
- Pennsylvania Fair Contracting for Health Care Practitioners Act
- Pennsylvania External Review Success Data
Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance policies and state regulations change frequently. Always verify current requirements with your specific plan and consult healthcare professionals for medical decisions. For personalized assistance with appeals and prior authorizations, contact the Pennsylvania Insurance Department Consumer Services at 1-877-881-6388.
Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.